These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

109 related articles for article (PubMed ID: 7569670)

  • 1. Toxicokinetics/toxicodynamic correlations: goals, methods, and limitations.
    Batra VK
    Toxicol Pathol; 1995; 23(2):158-64. PubMed ID: 7569670
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Considerations in the design of toxicokinetic programs.
    Cayen MN
    Toxicol Pathol; 1995; 23(2):148-57. PubMed ID: 7569669
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Differences between pharmacokinetics and toxicokinetics.
    Welling PG
    Toxicol Pathol; 1995; 23(2):143-7. PubMed ID: 7569668
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Using toxicokinetic-toxicodynamic modeling as an acute risk assessment refinement approach in vertebrate ecological risk assessment.
    Ducrot V; Ashauer R; Bednarska AJ; Hinarejos S; Thorbek P; Weyman G
    Integr Environ Assess Manag; 2016 Jan; 12(1):32-45. PubMed ID: 25833822
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Toxicokinetic and toxicodynamic considerations when deriving health-based exposure limits for pharmaceuticals.
    Reichard JF; Maier MA; Naumann BD; Pecquet AM; Pfister T; Sandhu R; Sargent EV; Streeter AJ; Weideman PA
    Regul Toxicol Pharmacol; 2016 Aug; 79 Suppl 1():S67-78. PubMed ID: 27224509
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Case report: quantification of methadone-induced respiratory depression using toxicokinetic/toxicodynamic relationships.
    Mégarbane B; Declèves X; Bloch V; Bardin C; Chast F; Baud FJ
    Crit Care; 2007; 11(1):R5. PubMed ID: 17224045
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Multi-organ-on-a-chip for pharmacokinetics and toxicokinetic study of drugs.
    Sung JH
    Expert Opin Drug Metab Toxicol; 2021 Aug; 17(8):969-986. PubMed ID: 33764248
    [No Abstract]   [Full Text] [Related]  

  • 8. Linking Morphology, Toxicokinetic, and Toxicodynamic Traits of Aquatic Invertebrates to Pyrethroid Sensitivity.
    Dalhoff K; Hansen AMB; Rasmussen JJ; Focks A; Strobel BW; Cedergreen N
    Environ Sci Technol; 2020 May; 54(9):5687-5699. PubMed ID: 32227918
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Magnitude and mechanistic determinants of the interspecies toxicokinetic uncertainty factor for organic chemicals.
    Pelekis M; Krishnan K
    Regul Toxicol Pharmacol; 2004 Dec; 40(3):264-71. PubMed ID: 15546680
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Predictive models in ecotoxicology: Bridging the gap between scientific progress and regulatory applicability-Remarks and research needs.
    Vighi M; Barsi A; Focks A; Grisoni F
    Integr Environ Assess Manag; 2019 May; 15(3):345-351. PubMed ID: 30821044
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Dose selection for toxicity studies: a protocol for determining the maximum repeatable dose.
    Spurling NW; Carey PF
    Hum Exp Toxicol; 1992 Nov; 11(6):449-57. PubMed ID: 1361132
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Variations of pharmacokinetics of drugs in patients with cirrhosis.
    Pena MA; Horga JF; Zapater P
    Expert Rev Clin Pharmacol; 2016; 9(3):441-58. PubMed ID: 26696448
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The toxicokinetics and toxicodynamics of organophosphonates versus the pharmacokinetics and pharmacodynamics of oxime antidotes: biological consequences.
    Voicu VA; Thiermann H; Rădulescu FS; Mircioiu C; Miron DS
    Basic Clin Pharmacol Toxicol; 2010 Feb; 106(2):73-85. PubMed ID: 19961476
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Highly time-variable exposure to chemicals--toward an assessment strategy.
    Ashauer R; Brown CD
    Integr Environ Assess Manag; 2013 Jul; 9(3):e27-33. PubMed ID: 23564608
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Significance of ICH--toxicokinetics guidance and its practice--a useful approach for safety drug development].
    Tsuda M; Ohno Y
    Kokuritsu Iyakuhin Shokuhin Eisei Kenkyusho Hokoku; 1997; (115):1-14. PubMed ID: 9641814
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A toxicity risk index, an index for warning idiosyncratic drug toxicity.
    Morimoto M; Samizo K; Ohta S; Mizuma T
    J Pharm Sci; 2013 Sep; 102(9):3447-50. PubMed ID: 23666879
    [TBL] [Abstract][Full Text] [Related]  

  • 17. ICH discussion on pharmacokinetics and toxicokinetics and contributors.
    Ohno Y
    Drug Metab Pharmacokinet; 2013; 28(5):379-82. PubMed ID: 24162438
    [No Abstract]   [Full Text] [Related]  

  • 18. Advantages of toxicokinetics in new drug development.
    Horii I
    Toxicol Lett; 1998 Dec; 102-103():657-64. PubMed ID: 10022331
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pharmacokinetics and toxicokinetics of bio-pharmaceuticals: technical problems.
    Kawai M
    J Toxicol Sci; 1996 Dec; 21(5):535-7. PubMed ID: 9035067
    [No Abstract]   [Full Text] [Related]  

  • 20. Drugs in control samples in nonclinical safety studies: a reconsideration.
    Zimmer D
    Bioanalysis; 2016 May; 8(10):1003-7. PubMed ID: 27080047
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.